Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Advanced Oncotherapy plc (AVO) Ord 25p

Sell:29.00p Buy:32.00p 0 Change: No change
Market closed Prices as at close on 27 November 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:29.00p
Buy:32.00p
Change: No change
Market closed Prices as at close on 27 November 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:29.00p
Buy:32.00p
Change: No change
Market closed Prices as at close on 27 November 2020 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Advanced Oncotherapy Plc is focused on providing radiotherapy systems for cancer treatment through the use of a proton therapy technology. The Company is engaged in development and then building of the Linac Image Guided Hadron Technology (LIGHT) proton beam cancer therapy device. The Company's segments include Development of Proton Therapy-UK; Development of Proton Therapy-Switzerland; Development of Proton Therapy-USA, and Healthcare-related properties-UK. Its LIGHT system integrates a series of modular linear accelerators. This feature offers hospitals and centers to customize treatment plans based on a range of energies. The Company's Research and development/ADAM S.A. (R&D/ADAM) facility is located on the campus of European Council for Nuclear Research (CERN), Geneva and Switzerland. The Company’s verification and validation site is located in Daresbury, United Kingdom.

Contact details

Address:
Third Fl, 4 Tenterden Street
LONDON
W1S 1TE
United Kingdom
Telephone:
+44 (020) 36178728
Website:
https://www.avoplc.com/

Important dates

Future events
There are no future events available.
Past events
Interim results 29 September 2020 29/09/20
AGM 29 July 2020 29/07/20
Final results 29 June 2020 29/06/20
AGM 11 May 2020 11/05/20
General meeting 11 May 2020 11/05/20

General stock information

EPIC:
AVO
ISIN:
GB00BD6SX109
Market cap:
£101.70 million
Shares in issue:
333.44 million
Sector:
Health Care Equipment & Services
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Michael Sinclair
    Executive Chairman of the Board
  • Nicolas Serandour
    Chief Executive Officer, Executive Director
  • Ed Lee
    Chief Operating Officer, President, Europe
  • Geraldine Poindron
    Senior Vice President - Corporate Finance
  • Berengere Pons - Chabord
    Senior Vice President - Corporate Finance
  • Louise Harley-Smeur
    Senior Vice President - Intellectual Property
  • Graham Pughe
    Senior Vice-President - Accounting and IT
  • Steve Myers
    Executive Director, Executive Chairman ADAM
  • Bridget Biggar
    Director of Human Resources
  • Michel Baelen
    Director - Regulatory Affairs

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.